Convatech at ICBC Berlin New partners introduced in the ICBC Berlin forum We are present to show and obtain feedback on a novel oral once daily Fixed Dose Combination Tablet which contains rifampicin and clarithromycin that could facilitate the treatment

Development of a new leishmaniasis drug wins EU funding TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of Neglected Infectious Diseases (NID) and its social and economic impacts. Horizon 2020,

How to make a DIY Hand Disinfection Spray With the current coronavirus, face caps and disinfectant soap and hand gel are hardly available in the stores. Although you can discuss the usefulness of face masks, washing your hands regularly is

Convatech participates in a consortium to develop new medicines to treat and prevent COVID-19 The public-private consortium to run this project includes leading academic groups and for-profit parties with a track record in drug discovery and development, extensive knowledge of

Repurposing Antimalarials to Tackle the COVID-19 Pandemic An international group of researchers, including Convatech CEO Hans Platteeuw, believe there is ample evidence that antimalarial drugs can be used to treat COVID-19 and that they should be assessed for their efficacy